Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

takeda_world

Takeda’s investigational therapy shows promise as cytomegalovirus treatment

September 25, 2019 Research and Development, Sales and Marketing Takeda, cytomegalovirus, maribavir, pharma

New Phase 2 data has been released on Takeda’s investigational antiviral therapy TAK-620 (maribavir) in patients with cytomegalovirus (CMV) infection …
News
novartis_side_building

Novartis blames former AveXis execs for Zolgensma data manipulation

September 25, 2019 Research and Development

Novartis has placed blame on former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million …
News
opdivo_1_1

EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma

September 25, 2019 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …
News
Ipsen Logo

Ipsen announces positive phase 3 results in limb spastic hemiparesis

September 24, 2019 Manufacturing and Production, Research and Development

Ipsen has announced results from its ENGAGE study for the combination of Dysport (abobotulinumtoxinA) alongside Guided Self-rehabilitation contracts (GSC) which …
News
Takeda HQ

Evotec and Takeda enter into multi therapeutic area collaboration

September 24, 2019 Manufacturing and Production, Research and Development

Evotec have announced a strategic, multi-year drug discovery collaboration with Takeda, with both companies aiming to establish at least five …
News

Bayer’s Vitravki becomes first EU-approved tumour-agnostic therapy

September 24, 2019 Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Cancer, Vitravki, pharma

Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for …
News
images

Medicinal cannabis product Epidyolex approved in EU for childhood epilepsy

September 24, 2019 Manufacturing and Production, Research and Development

GW Pharmaceuticals, a world leader in the development of cannabinoid prescription drugs has announced it has received approval from the …
News

Destiny Pharma’s Joe Eagle to step down from Board

September 23, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs to address the global crisis …
Appointment

Living with acute myeloid leukaemia

September 23, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acute myeloid leukaemia, feature, patient experience, pharma

Steve Rothberg was blindsided by an AML diagnosis that progressed rapidly with little warning. Ten years later, he discusses his …
Feature
bluebird_bio_external_durham_nc_manufacturing

Bluebird bio’s Lenti-D gene therapy shows promise in cerebral adrenoleukodystrophy

September 23, 2019 Research and Development, Sales and Marketing Bluebird Bio, cerebral adrenoleukodystrophy, gene therapy, pharma

Bluebird bio has revealed updated data for its investigational Lenti-D gene therapy in the treatment of cerebral adrenoleukodystrophy (CALD), a …
News
800px-zoloft_50_mg_cn

Antidepressant sertraline works ‘by reducing anxiety symptoms first’

September 20, 2019 Medical Communications, Research and Development antidepressant, sertraline

Researchers at University College London have found that a commonly prescribed antidepressant, sertraline, works in unexpected ways, first relieving users …
News
novo_flag

Novo’s Tresiba lowers hypoglycaemia risk compared to insulin glargine in type 2 diabetes

September 20, 2019 Medical Communications, Research and Development Novo Nordisk, Tresiba, diabetes, pharma

Novo Nordisk has unveiled new data for Tresiba (insulin degludec) at the 55th Annual Meeting of the European Association for …
News
biogen_austria_238

Biogen to start new Spinraza trial to preserve market share

September 20, 2019 Medical Communications, Research and Development

Biogen is planning a new trial of $1.7billion-a-year Spinraza to investigate much higher doses in spinal muscular atrophy (SMA) and …
News
researchers_credit_neusentis_pfizer

Almost half of all cancer drug trials show bias and exaggeration

September 19, 2019 Research and Development BMJ, Cancer, cancer drug trials

New research on clinical trials between 2014 and 2016 raise “serious concerns about low standards” as over the three year …
News

Sanofi’s Troujeo beats insulin degludec in head-to-head study in type 2 diabetes

September 19, 2019 Research and Development Sanofi, Troujeo, diabetes, insulin degludec, pharma

Sanofi took the opportunity at the 55th annual European Association for the Study of Diabetes to present new data from …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026